<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Public Health</journal-id>
<journal-title>Frontiers in Public Health</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Public Health</abbrev-journal-title>
<issn pub-type="epub">2296-2565</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpubh.2021.747894</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Public Health</subject>
<subj-group>
<subject>Perspective</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Applying the Hierarchy of Controls: What Occupational Safety Can Teach us About Safely Navigating the Next Phase of the Global COVID-19 Pandemic</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Sehgal</surname> <given-names>Neil J.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1420822/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Milton</surname> <given-names>Donald K.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/61840/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Health Policy and Management, University of Maryland School of Public Health</institution>, <addr-line>College Park, MD</addr-line>, <country>United States</country></aff>
<aff id="aff2"><sup>2</sup><institution>Maryland Institute for Applied Environmental Health, University of Maryland School of Public Health</institution>, <addr-line>College Park, MD</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Marc Jean Struelens, Universit&#x000E9; libre de Bruxelles, Belgium</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Liliane Okdah, King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia; Patrick O&#x00027;Shaughnessy, The University of Iowa, United States; David Michaels, George Washington University, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Neil J. Sehgal <email>sehgal&#x00040;umd.edu</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health</p></fn></author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>747894</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>07</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2021 Sehgal and Milton.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Sehgal and Milton</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract><p>Eighteen months into the COVID-19 pandemic, and as the world struggles with global vaccine equity, emerging variants, and the reality that eradication is years away at soonest, we add to notion of &#x0201C;layered defenses&#x0201D; proposing a conceptual model for better understanding the differential applicability and effectiveness of precautions against SARS-CoV-2 transmission. The prevailing adaptation of Reason&#x00027;s Swiss cheese model conceives of all defensive layers as equally protective, when in reality some are more effective than others. Adapting the hierarchy of controls framework from occupational safety provides a better framework for understanding the relative benefit of different hazard control strategies to minimize the spread of SARS-CoV-2.</p></abstract>
<kwd-group>
<kwd>COVID-19</kwd>
<kwd>SARS-CoV-2</kwd>
<kwd>transmission</kwd>
<kwd>hierarchy of controls</kwd>
<kwd>layered defenses</kwd>
<kwd>layered prevention</kwd>
<kwd>PPE</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="18"/>
<page-count count="4"/>
<word-count count="2286"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>The recent popularity (<xref ref-type="bibr" rid="B1">1</xref>) of the application of James Reason&#x00027;s Swiss cheese model of accident causation to COVID-19 transmission falls short in one important regard&#x02014;the successive &#x0201C;layers&#x0201D; of defense are too easily perceived as equally effective to control the hazard. A preponderance of evidence now demonstrates that this is not the case (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). Inadequacy in defenses and differential risk (e.g., fabric face coverings as compared to filtering respirators, and aerosol &#x0201C;super-spreading&#x0201D; as compared to droplet or fomite transmission) requires a different approach to conceptualizing COVID-19 risk reduction&#x02014;particularly as COVID-19 continues to devastate the developing world, new and more transmissible variants emerge, vaccines are not yet equitably available across the globe, and eradication of SARS-CoV-2 is decreasingly likely (<xref ref-type="bibr" rid="B4">4</xref>). Additionally, framing defensive layers as equally effective may poses challenges to the adoption of more effective mitigation strategies (e.g., vaccination), when the adoption of seemingly equivalent protections may be preferable (<xref ref-type="bibr" rid="B5">5</xref>).</p>
</sec>
<sec id="s2">
<title>The Hierarchy of Controls</title>
<p>The hierarchy of controls is a framework employed in occupational safety and health to better understand the relative effectiveness of different strategies for risk reduction, and to help determine how to implement feasible and effective solutions (<xref ref-type="bibr" rid="B6">6</xref>). The model (<xref ref-type="fig" rid="F1">Figure 1</xref>) is represented as an upside-down pyramid, with five categories represented in descending order of effectiveness: elimination, substitution, engineering controls, administrative controls, and personal protective equipment (PPE). And, while developed to better manage exposures to occupational hazards and protect workers, the model has broad applicability in helping healthcare workers, policy makers, and the public better understand the relative effectiveness of strategies to prevent the transmission of an airborne infectious virus like SARS-CoV-2, and the paradigm is increasingly being adopted to conceptualize COVID-19 risk reduction (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). The fundamental idea behind the hierarchy is that, while different hazard controls are effective at minimizing risk, those at the top of the model are more protective than those at the bottom. As in occupational safety and health, employing the most effective methods first and most frequently can best minimize the risk of COVID-19 transmission.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>The hierarchy of COVID-19 controls.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fpubh-09-747894-g0001.tif"/>
</fig>
<p>Recent revisions to Centers for Disease Control and Prevention guidance on transmission notes &#x0201C;infections with respiratory viruses are principally transmitted through three modes: contact, droplet, and airborne.&#x0201D; (<xref ref-type="bibr" rid="B9">9</xref>) Contact or &#x0201C;fomite&#x0201D; transmission occurs through touching an infectious person or a surface or item that is contaminated with virus. Droplet transmission occurs through exposure to virus-containing respiratory droplets directly from an infectious person to a susceptible person at close range. Airborne transmission occurs through exposure to smaller virus-containing droplets and particles that float in the air, are highly concentrated close to the person who exhaled them and can remain suspended in air for many seconds to hours and accumulate in the air of poorly ventilated spaces. A key weakness in early COVID-19 response was in treating these hazards as equivalent; recent research has demonstrated comparatively low risk of contact transmission (<xref ref-type="bibr" rid="B10">10</xref>), and the World Health Organization has noted that despite evidence of the survival of SARS-CoV-2 on certain surfaces, no reports have directly demonstrated fomite transmission (<xref ref-type="bibr" rid="B11">11</xref>). Emerging evidence, on the other hand, suggests significant risk associated with close-contact transmission over short distances and in poorly ventilated spaces, with airborne transmission making the largest contribution (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). Though protecting against each of these hazards is necessary, currently employed controls are not equally effective against each, and higher-order controls should be prioritized.</p>
<sec>
<title>Elimination and Substitution</title>
<p>Elimination and substitution, the most effective hazard controls, involve physically removing the hazard and associated risk or substituting the hazard with something less risky. Stay-at-home orders employed early in the pandemic were attempts to eliminate transmission risk in communities. While in principle effective, the dire social, psychological, and economic impacts of &#x0201C;lock-downs&#x0201D; limits their long-term viability and necessitate that they be used only briefly while other measures are put in place. Isolation and quarantine are additional means of eliminating transmission risk from infected or potentially infectious individuals. As a precautionary measure, eliminating unnecessary public outings or gatherings is another effective means of removing the risk of SARS-CoV-2 infection. Similarly, allowing remote work or moving indoor-activities outdoors substitutes the hazards incumbent in in-person activities with less risky alternatives. Vaccines against COVID-19 have proven to be a very effective pharmacologic elimination strategy where available.</p>
</sec>
<sec>
<title>Engineering Controls</title>
<p>Engineering controls do not eliminate hazards, but rather isolate individuals from them. Physical barriers separating individuals who must interact at close range are a now very common example of an engineering control. Importantly, however, as they do not eliminate hazards engineering controls must be employed in concert with other controls. Improving the safety of indoor air by increasing ventilation and filtration or employing upper-room germicidal ultraviolet light are as-yet underemployed engineering controls which can further minimize COVID-19 transmission risk (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). Well-designed engineering controls can be highly effective, reducing risk to individuals independent of their own behaviors, and can significantly enhance protection for individuals adherent to administrative controls or employing PPE (<xref ref-type="bibr" rid="B16">16</xref>). A key limitation of engineering controls as a community mitigation strategy is that, unlike in industry, it is not always possible to redesign indoor spaces, ventilation systems, and other infrastructure to sufficiently ameliorate the risk of pathogenic transmission. Where engineering controls are able to limit concentrations of indoor respiratory aerosols, however, they are effective in reducing &#x0201C;far-field&#x0201D; airborne transmission of infectious agents like SARS-CoV-2.</p>
</sec>
<sec>
<title>Administrative Controls</title>
<p>Administrative controls involve changing individual behaviors via policy or mandate to minimize hazard risk, and are the control most frequently instituted to increase social distancing, and to reduce person-to-person interaction or population density in defined spaces to protect against COVID-19 infection. Policies restricting indoor activities like large gatherings or dining, and organizational-level mandates like remote-work, staggered in-person work schedules, or distance learning are administrative means of minimizing density-attributed risk. Vaccine and mask-mandates are another administrative control, though their effectiveness has been limited by social and political resistance. This illustrates the key weakness of reliance on administrative controls (and the challenge in relying exclusively on them to mitigate transmission risk); compliance is necessary for administrative controls to be effective, and even well-intentioned individuals are prone to slips and lapses in adherence. And, as lessons from patient safety and risk management teach, policies that rely on perfect adherence are inadequate and doomed to fail.</p>
</sec>
<sec>
<title>Personal Protective Equipment</title>
<p>The final risk reduction strategy is the employment of PPE, protecting individuals from known hazard exposure using respirators, eye protection, and other individually donned protective items. PPE can reduce risk of hazard and its use has been an essential strategy to limit COVID-19 transmission, though it is necessarily less protective than controls higher in the hierarchy. The effectiveness of PPE as a control is additionally limited as it is reliant on both adequate supply and proper and continuous use. In circumstances where hazards are truly unavoidable, PPE use is critical. In work-settings reliant on PPE for hazard control, regulations mandate additional controls as well. Lay-persons are infrequently trained in the correct use of PPE, and in the current pandemic frequently ill-equipped&#x02014;non-medical masks and fabric face coverings are not PPE, and wearing a non-medical mask does not eliminate SARS-CoV-2 infection risk to the individual (<xref ref-type="bibr" rid="B17">17</xref>).</p>
</sec>
</sec>
<sec sec-type="discussion" id="s3">
<title>Discussion</title>
<p>As it is increasingly likely that COVID-19 will remain endemic, as more transmissible variants emerge, and as at our current pace we may not vaccinate people in low-income countries until the end of 2022 or beyond (<xref ref-type="bibr" rid="B18">18</xref>), our continued reliance on the least effective controls and our continued treatment of controls as substitutes instead of complements&#x02014;such as reliance on face-coverings or social distancing, but not both&#x02014;has limited our ability to keep SARS-CoV2 in-check. The hierarchy of controls is an effective model for understanding both the relative effectiveness of hazard minimization, and that while most strategies are necessary few are sufficient to slow the spread of COVID-19.</p>
</sec>
<sec sec-type="data-availability" id="s4">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s5">
<title>Author Contributions</title>
<p>NS conceptualized the piece and drafted the first version of the manuscript. NS and DM commented on and edited the draft. Both authors reviewed and agreed with the final version.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s6">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="web"><person-group person-group-type="author"><name><surname>Roberts</surname> <given-names>S</given-names></name></person-group>. <article-title>The swiss cheese model of pandemic defense</article-title>. <source>The New York Times</source> (2020, June 30). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.nytimes.com/2020/12/05/health/coronavirus-swiss-cheese-infection-mackay.html">https://www.nytimes.com/2020/12/05/health/coronavirus-swiss-cheese-infection-mackay.html</ext-link>.</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname> <given-names>DK</given-names></name> <name><surname>Akl</surname> <given-names>EA</given-names></name> <name><surname>Duda</surname> <given-names>S</given-names></name> <name><surname>Solo</surname> <given-names>K</given-names></name> <name><surname>Yaacoub</surname> <given-names>S</given-names></name> <name><surname>Sch&#x000FC;nemann</surname> <given-names>HJ</given-names></name> <etal/></person-group>. <article-title>Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>1973</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31142-9</pub-id><pub-id pub-id-type="pmid">32497510</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>M</given-names></name> <name><surname>Zu</surname> <given-names>J</given-names></name> <name><surname>Fairley</surname> <given-names>CK</given-names></name> <name><surname>Pag&#x000E1;n</surname> <given-names>JA</given-names></name> <name><surname>An</surname> <given-names>L</given-names></name> <name><surname>Du</surname> <given-names>Z</given-names></name> <etal/></person-group>. <article-title>Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use</article-title>. <source>Vaccine.</source> (<year>2021</year>) <volume>39</volume>:<fpage>2295</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.02.056</pub-id><pub-id pub-id-type="pmid">33771391</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname> <given-names>CJL</given-names></name> <name><surname>Piot</surname> <given-names>P</given-names></name></person-group>. <article-title>The potential future of the COVID-19 pandemic: will SARS-CoV-2 become a recurrent seasonal infection?</article-title> <source>JAMA.</source> (<year>2021</year>) <volume>325</volume>:<fpage>1249</fpage>. <pub-id pub-id-type="doi">10.1001/jama.2021.2828</pub-id><pub-id pub-id-type="pmid">33656519</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trogen</surname> <given-names>B</given-names></name> <name><surname>Caplan</surname> <given-names>A</given-names></name></person-group>. <article-title>Risk compensation and COVID-19 vaccines</article-title>. <source>Ann Intern Med.</source> (<year>2021</year>) <volume>174</volume>:<fpage>858</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.7326/M20-8251</pub-id><pub-id pub-id-type="pmid">33646837</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="web"><person-group person-group-type="author"><collab>The National Institute for Occupational Safety and Health</collab></person-group>. <source>Hierarchy of Controls</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/niosh/topics/hierarchy/default.html">https://www.cdc.gov/niosh/topics/hierarchy/default.html</ext-link> (accessed October 1, 2021)</citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="web"><person-group person-group-type="author"><collab>The National Institute for Occupational Safety and Health Department of Labor</collab></person-group>. <source>Guidance on Preparing Workplaces for COVID-19 (OSHA 3990-02 2020)</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.osha.gov/sites/default/files/publications/OSHA3990.pdf">https://www.osha.gov/sites/default/files/publications/OSHA3990.pdf</ext-link> (accessed October 1, 2021)</citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="web"><person-group person-group-type="author"><collab>American Society of Safety Professionals</collab></person-group>. <source>How to Apply the Hierarchy of Controls in a Pandemic</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.assp.org/news-and-articles/how-to-apply-the-hierarchy-of-controls-in-a-pandemic">https://www.assp.org/news-and-articles/how-to-apply-the-hierarchy-of-controls-in-a-pandemic</ext-link> (accessed October 1, 2021)</citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="web"><person-group person-group-type="author"><collab>CDC</collab></person-group>. <article-title>Coronavirus Disease 2019 (COVID-19)</article-title>. <source>Centers for Disease Control and Prevention.</source> (<year>2020</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html">https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html</ext-link> (accessed June 30, 2021)</citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mondelli</surname> <given-names>MU</given-names></name> <name><surname>Colaneri</surname> <given-names>M</given-names></name> <name><surname>Seminari</surname> <given-names>EM</given-names></name> <name><surname>Baldanti</surname> <given-names>F</given-names></name> <name><surname>Bruno</surname> <given-names>R</given-names></name></person-group>. <article-title>Low risk of SARS-CoV-2 transmission by fomites in real-life conditions</article-title>. <source>Lancet Infect Dis.</source> (<year>2021</year>) <volume>21</volume>:<fpage>e112</fpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30678-2</pub-id><pub-id pub-id-type="pmid">33007224</pub-id></citation></ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="web"><person-group person-group-type="author"><collab>Transmission of SARS-CoV-2: Implications for Infection Prevention Precautions</collab></person-group>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions">https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions</ext-link> (accessed June 30, 2021)</citation>
</ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamner</surname> <given-names>L</given-names></name></person-group>. <article-title>High SARS-CoV-2 attack rate following exposure at a choir practice&#x02014;Skagit County, Washington, march 2020</article-title>. <source>MMWR Morb Mortal Wkly Rep.</source> (<year>2020</year>) <volume>69</volume>:<fpage>606</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm6919e6</pub-id><pub-id pub-id-type="pmid">32407303</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname> <given-names>S</given-names></name> <name><surname>Han</surname> <given-names>SH</given-names></name> <name><surname>Rhee</surname> <given-names>J-Y</given-names></name></person-group>. <article-title>Cluster of coronavirus disease associated with fitness dance classes, South Korea</article-title>. <source>Emerg Infect Dis.</source> (<year>2020</year>) <volume>26</volume>:<fpage>1917</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.3201/eid2608.200633</pub-id><pub-id pub-id-type="pmid">32412896</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morawska</surname> <given-names>L</given-names></name> <name><surname>Milton</surname> <given-names>DK</given-names></name></person-group>. <article-title>It is time to address airborne transmission of coronavirus disease 2019 (COVID-19)</article-title>. <source>Clin Infect Dis</source>. (<year>2020</year>) <volume>71</volume>:<fpage>2311</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa939</pub-id><pub-id pub-id-type="pmid">32628269</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morawska</surname> <given-names>L</given-names></name> <name><surname>Allen</surname> <given-names>J</given-names></name> <name><surname>Bahnfleth</surname> <given-names>W</given-names></name> <name><surname>Bluyssen</surname> <given-names>PM</given-names></name> <name><surname>Boerstra</surname> <given-names>A</given-names></name> <name><surname>Buonanno</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title>A paradigm shift to combat indoor respiratory infection</article-title>. <source>Science.</source> (<year>2021</year>) <volume>372</volume>:<fpage>689</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1126/science.abg2025</pub-id><pub-id pub-id-type="pmid">33986171</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname> <given-names>JG</given-names></name> <name><surname>Ibrahim</surname> <given-names>AM</given-names></name></person-group>. <article-title>Indoor air changes and potential implications for SARS-CoV-2 transmission</article-title>. <source>JAMA.</source> (<year>2021</year>) <volume>325</volume>:<fpage>2112</fpage>. <pub-id pub-id-type="doi">10.1001/jama.2021.5053</pub-id><pub-id pub-id-type="pmid">33861316</pub-id></citation></ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname> <given-names>M</given-names></name> <name><surname>Marr</surname> <given-names>LC</given-names></name></person-group>. <article-title>Uniting infectious disease and physical science principles on the importance of face masks for COVID-19</article-title>. <source>Med.</source> (<year>2021</year>) <volume>2</volume>:<fpage>29</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.medj.2020.12.008</pub-id><pub-id pub-id-type="pmid">33521753</pub-id></citation></ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname> <given-names>A</given-names></name></person-group>. <article-title>What it will take to vaccinate the world against COVID-19</article-title>. <source>Nature.</source> (<year>2021</year>) <volume>592</volume>:<fpage>176</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/d41586-021-00727-3</pub-id><pub-id pub-id-type="pmid">33767468</pub-id></citation></ref>
</ref-list>
</back>
</article>
